Perplexities of treatment resistence in eating disorders

BackgroundTreatment resistance is an omnipresent frustration in eating disorders. Attempts to identify the features of this resistance and subsequently develop novel treatments have had modest effects. This selective review examines treatment resistant features expressed in core eating disorder psychopathology, comorbidities and biological features. Novel treatments addressing resistance are discussed.DescriptionThe core eating disorder psychopathology of anorexia nervosa becomes a coping mechanism likely via vulnerable neurobiological features and conditioned learning to deal with life events. Thus it is reinforcing and ego syntonic resulting in resistance to treatment. The severity of core features such as preoccupations with body image, weight, eating and exercising predicts greater resistance to treatment. Bulimia nervosa patients are less resistant to treatment with treatment failure related to greater body image concerns, impulsivity, depression, severe diet restriction and poor social adjustment. For those with binge eating disorder overweight in childhood and high emotional eating predicts treatment resistance. There is suggestive data that a diagnosis of an anxiety disorder and severe perfectionism may confer treatment resistance in anorexia nervosa and substance use disorders or personality disorders with impulse control problems may produce resistance to treatment in bulimia nervosa. Traits such as perfectionism, cognitive inflexibility and negative affect with likely genetic influences may also affect treatment resistance. Pharmacotherapy and novel therapies have been developed to address treatment resistance. Atypical antipsychotic drugs have shown some effect in treatment resistant anorexia nervosa and topiramate and high doses of SSRIs are helpful for treatment of resistant binge eating disorder patients. There are insufficient randomized controlled trials to evaluate the novel psychotherapies which are primarily based on the core psychopathological features of the eating disorders.ConclusionTreatment resistance in eating disorders is usually predicted by the severity of the core eating disorder psychopathology which develops from an interaction between environmental risk factors with genetic traits and a vulnerable neurobiology. Future investigations of the biological features and neurocircuitry of the core eating disorders psychopathology and behaviors may provide information for more successful treatment interventions.

[1]  T. Wadden,et al.  Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. , 2001, Archives of internal medicine.

[2]  C. Grilo,et al.  Pharmacological treatment of binge eating disorder: update review and synthesis , 2015, Expert opinion on pharmacotherapy.

[3]  C. Bulik,et al.  Comorbidity of anxiety disorders with anorexia and bulimia nervosa. , 2004, The American journal of psychiatry.

[4]  B. Rooney,et al.  Compliance and outcome in treatment-resistant anorexia and bulimia: a retrospective study. , 2001, The British journal of clinical psychology.

[5]  C. Bulik,et al.  Symptom fluctuation in eating disorders: correlates of diagnostic crossover. , 2005, The American journal of psychiatry.

[6]  D. Zuroff,et al.  Self-compassion and fear of self-compassion interact to predict response to eating disorders treatment: A preliminary investigation , 2013, Psychotherapy research : journal of the Society for Psychotherapy Research.

[7]  P. Joyce,et al.  Specialist supportive clinical management for anorexia nervosa. , 2006, The International journal of eating disorders.

[8]  J. Treasure,et al.  A case series evaluation of the Maudsley Model for treatment of adults with anorexia nervosa. , 2011, European eating disorders review : the journal of the Eating Disorders Association.

[9]  M. Strober Managing the chronic, treatment-resistant patient with anorexia nervosa. , 2004, The International journal of eating disorders.

[10]  H. Kraemer,et al.  Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. , 2005, Archives of general psychiatry.

[11]  R. Kessler,et al.  The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication , 2007, Biological Psychiatry.

[12]  Elena Moreno,et al.  Cue exposure in the treatment of resistant adolescent bulimia nervosa. , 2007, The International journal of eating disorders.

[13]  K. Halmi,et al.  Psychiatric comorbidity in patients with eating disorders , 1994, Psychological Medicine.

[14]  H. Kraemer,et al.  Outcome predictors for the cognitive behavior treatment of bulimia nervosa: data from a multisite study. , 2000, The American journal of psychiatry.

[15]  W. Kaye Neurobiology of anorexia and bulimia nervosa , 2008, Physiology & Behavior.

[16]  C. Faravelli,et al.  Cognitive-Behavioral Therapy for Threshold and Subthreshold Anorexia Nervosa: A Three-Year Follow-Up Study , 2010, Psychotherapy and Psychosomatics.

[17]  N. Schork,et al.  5-HT₁A receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. , 2011, The International journal of eating disorders.

[18]  K. Halmi,et al.  Changing patterns of hospitalization in eating disorder patients. , 2001, The International journal of eating disorders.

[19]  W. Agras,et al.  Subtyping binge eating-disordered women along dieting and negative affect dimensions. , 2001, The International journal of eating disorders.

[20]  N. Schork,et al.  Genetic Association of Recovery from Eating Disorders: The Role of GABA Receptor SNPs , 2011, Neuropsychopharmacology.

[21]  H. Kraemer,et al.  Stepped care and cognitive–behavioural therapy for bulimia nervosa: randomised trial , 2011, British Journal of Psychiatry.

[22]  K. Tchanturia,et al.  A Case Study Introducing Cognitive Remediation and Emotion Skills Training for Anorexia Nervosa Inpatient Care , 2011 .

[23]  K. Halmi,et al.  The sense of personal ineffectiveness in patients with eating disorders: One construct or several? , 1987 .

[24]  H. Steiger,et al.  The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. , 2005, The International journal of eating disorders.

[25]  C. Bulik,et al.  Anorexia nervosa trios: behavioral profiles of individuals with anorexia nervosa and their parents , 2008, Psychological Medicine.

[26]  S. McElroy,et al.  Pharmacologic treatment of binge eating disorder. , 2003, The International journal of eating disorders.

[27]  M. Miniati,et al.  Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. , 2003, The International journal of eating disorders.

[28]  Katherine D. Arnow,et al.  Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report. , 2012, Innovations in clinical neuroscience.

[29]  D. Collier,et al.  Set shifting in anorexia nervosa: an examination before and after weight gain, in full recovery and relationship to childhood and adult OCPD traits. , 2004, Journal of psychiatric research.

[30]  J. Vanderlinden Many roads lead to Rome: Why does cognitive behavioural therapy remain unsuccessful for many eating disorder patients? , 2008, European eating disorders review : the journal of the Eating Disorders Association.

[31]  J. Geller,et al.  Setting the eating disorder aside: an alternative model of care. , 2010, European eating disorders review : the journal of the Eating Disorders Association.

[32]  M. Gladis,et al.  Long-term outcome of antidepressant treatment for bulimia nervosa. , 1991, The American journal of psychiatry.

[33]  H. Steiner,et al.  Habitual Response to Stress in Recovering Adolescent Anorexic Patients , 2009, Child psychiatry and human development.

[34]  N. Schork,et al.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa , 2013, Psychiatry Research: Neuroimaging.

[35]  M. Buchsbaum,et al.  Serotonin transporter binding after recovery from bulimia nervosa. , 2012, The International journal of eating disorders.

[36]  B. Devlin,et al.  Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[37]  P. Keel,et al.  Outcome in bulimia nervosa. , 1997, The American journal of psychiatry.

[38]  B. Devlin,et al.  Alcohol use disorder comorbidity in eating disorders: a multicenter study. , 2004, The Journal of clinical psychiatry.

[39]  D. M.,et al.  Perfectionism in anorexia nervosa: variation by clinical subtype, obsessionality, and pathological eating behavior. , 2000, The American journal of psychiatry.

[40]  I. Campbell,et al.  Cognitive remediation therapy for patients with anorexia nervosa: preliminary findings , 2007, Annals of general psychiatry.

[41]  K. Halmi Perplexities and provocations of eating disorders. , 2009, Journal of child psychology and psychiatry, and allied disciplines.

[42]  C. Faravelli,et al.  Comparison of individual and group cognitive behavioral therapy for binge eating disorder. A randomized, three-year follow-up study , 2010, Appetite.

[43]  G. Tasca,et al.  Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. , 2008, The American journal of psychiatry.

[44]  N. Leung,et al.  Existential well-being in younger and older people with anorexia nervosa--a preliminary investigation. , 2009, European eating disorders review : the journal of the Eating Disorders Association.

[45]  M. Romanos,et al.  Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports. , 2008, European eating disorders review : the journal of the Eating Disorders Association.